{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:39:48Z","timestamp":1791311988447,"version":"4.3.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s15010-019-01324-3","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T16:15:30Z","timestamp":1559664930000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco"],"prefix":"10.1007","volume":"48","author":[{"given":"Mariam","family":"El Hamdouni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Ahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal Eddine","family":"Bourkadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouda","family":"Benamor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Hassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahia","family":"Cherrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"1324_CR1","unstructured":"World Health Organization (2018) Global tuberculosis report. https:\/\/www.who.int\/tb\/publications\/global_report\/en\/."},{"key":"1324_CR2","unstructured":"Minist\u00e8re-de-la-Sant\u00e9-du-Maroc (2018) Plan strat\u00e9gique national pour la pr\u00e9vention et le contr\u00f4le de la tuberculose au Maroc 2018-2021.\u00a0https:\/\/www.smmg.ma\/publications\/documents\/1-programme-national-de-lutte-contre-la-tuberculose."},{"key":"1324_CR3","unstructured":"Minist\u00e8re-de-la-Sant\u00e9-du-Maroc (2011) Guide de lutte contre la tuberculose. In: ransmissibles Ddlclm, editor. 4th ed. Maroc."},{"issue":"11","key":"1324_CR4","first-page":"1","volume":"52","author":"Centers for Disease Control and Prevention American Thoracic Society, CDC, and Infectious Diseases Society of America","year":"2003","unstructured":"Centers for Disease Control and Prevention American Thoracic Society, CDC, and Infectious Diseases Society of America. Treatment of tuberculosis. Morb Mortal Wkly Rep. 2003;52(11):1\u201377.","journal-title":"Morb Mortal Wkly Rep"},{"key":"1324_CR5","first-page":"6","volume":"5","author":"H Elkhabbazi","year":"2015","unstructured":"Elkhabbazi H, Benkirane R, Khadmaoui A, Sefiani H, Quyou A, Mokhtari A, et al. Evaluation of adverse effects of antituberculosis In El-Idrissi Hospital, K\u00e9nitra, Morocco. IOSR J Pharm. 2015;5:6\u2013116.","journal-title":"IOSR J Pharm"},{"key":"1324_CR6","first-page":"634","volume":"7","author":"H Elkhabbazi","year":"2014","unstructured":"Elkhabbazi H, Benkirane R, Khadmaoui A, Sefiani H, Ouyou A, Mokhtari A, et al. Cutaneous adverse drug reactions in Morocco: a prospective study. Int J Innov Appl Stud. 2014;7:634\u201340.","journal-title":"Int J Innov Appl Stud"},{"key":"1324_CR7","first-page":"152","volume":"19","author":"SEM Alami","year":"2014","unstructured":"Alami SEM, Hammi S, Bourkadi JE. R\u00e9actions immunoallergiques graves aux antibacillaires: \u00e0 propos de 10 cas. Pan Afr Med J. 2014;19:152.","journal-title":"Pan Afr Med J"},{"key":"1324_CR8","unstructured":"Haut-Commissariat au Plan (2015) Population l\u00e9gale d\u2019apr\u00e8s les r\u00e9sultats du RGPH 2014 sur le Bulletin officiel No 6354 (in Arabic).\u00a0https:\/\/rgph2014.hcp.ma\/downloads\/Publications-RGPH-2014_t18649.html."},{"key":"1324_CR9","unstructured":"Taytard A (2005) Classement OMS des grades de toxicit\u00e9: RESPIR. F\u00e9d\u00e9ration Girondine de Lutte contre les Maladies Respiratoires (FGLMR): http:\/\/www.respir.com\/doc\/abonne\/pathologie\/cancerbronchique\/CBClassementOMSGradesToxicite.asp."},{"key":"1324_CR10","unstructured":"Soulaymani-Bencheikh R. Pharmacovigilance Course for Francophone Countries. In: MarocCAPedPd, editor. Imputabilit\u00e9 Concepts de Base et M\u00e9thodes: WHO, (2015)."},{"key":"1324_CR11","unstructured":"World Health Organization (2013) Definitions and reporting framework for tuberculosis.\u00a0https:\/\/www.who.int\/tb\/publications\/definitions\/en\/."},{"key":"1324_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0873-2159(15)30040-4","volume":"16","author":"AS Vilari\u00e7a","year":"2010","unstructured":"Vilari\u00e7a AS, Diogo N, Andr\u00e9 M, Pina J. Adverse\u00a0reactions to\u00a0antituberculosis\u00a0drugs in hospital patients: severity and risk factors. Rev Port Pneumol. 2010;16:431\u201351.","journal-title":"Rev Port Pneumol"},{"key":"1324_CR13","doi-asserted-by":"publisher","first-page":"e65037","DOI":"10.1371\/journal.pone.0065037.t005","volume":"8","author":"LV Xiaozhen","year":"2013","unstructured":"Xiaozhen LV, Shaowen T, Yinyin X, Xiaomeng W, Yanli Y, Daiyu H, et al. Adverse reactions due to directly observed treatment strategy therapy in chinese tuberculosis patients: a prospective study. PLOS One. 2013;8:e65037. https:\/\/doi.org\/10.1371\/journal.pone.0065037.t005.","journal-title":"PLOS One"},{"key":"1324_CR14","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","volume":"9","author":"T Schaberg","year":"1996","unstructured":"Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of Isoniazid, Rifampin and Pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9:2026\u201330.","journal-title":"Eur Respir J"},{"issue":"5","key":"1324_CR15","doi-asserted-by":"publisher","first-page":"e19566","DOI":"10.1371\/journal.pone.0019566","volume":"6","author":"N Lorent","year":"2011","unstructured":"Lorent N, Sebatunzi O, Mukeshimana G, Ende JVD, Clerinx J. Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study. PLoS One. 2011;6(5):e19566. https:\/\/doi.org\/10.1371\/journal.pone.0019566.","journal-title":"PLoS One"},{"key":"1324_CR16","first-page":"42","volume":"85","author":"S Taramian","year":"2012","unstructured":"Taramian S, Joukar F, Asgharnezhad M, Biabani A, Ghaney FM. Side effects of first-line anti tuberculosis drugs. J Guilan Univ Med Sci. 2012;85:42\u20137.","journal-title":"J Guilan Univ Med Sci"},{"key":"1324_CR17","first-page":"487","volume":"84","author":"L El Gharbi","year":"2006","unstructured":"El Gharbi L, Baccar MA, Azzabi S, Aouina H, Kallel H, Daghfous R, et al. Risk factors of side effects of antituberculosis drugs. Tunis Med. 2006;84:487\u201391.","journal-title":"Tunis Med"},{"key":"1324_CR18","first-page":"457","volume":"83","author":"Y Yamamoto","year":"2008","unstructured":"Yamamoto Y, Hayashi M, Miyakawa K, Ogawa K. Risk factors for side effects due to the use of antituberculous drugs in elderly patients. Kekkaku. 2008;83:457\u201363.","journal-title":"Kekkaku"},{"issue":"3","key":"1324_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6061\/clinics\/2013(03)OA08","volume":"68","author":"GS Damasceno","year":"2013","unstructured":"Damasceno GS, Guaraldo L, Engstrom EM, Filha MMTF, Santos RS, Vasconcelos AGG, et al. Adverse reactions to antituberculosisdrugs in Manguinhos, Rio de Janeiro, Brazil. Clinics. 2013;68(3):329\u201337.","journal-title":"Clinics"},{"key":"1324_CR20","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/pds.1468","volume":"16","author":"MR Javadi","year":"2007","unstructured":"Javadi MR, Shalviri G, Gholami K, Salamzadeh J, Maghooli G, Mirsaeedi SM. Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors. Pharmacoepidemiol Drug Safe. 2007;16:1104\u201310.","journal-title":"Pharmacoepidemiol Drug Safe"},{"key":"1324_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1590\/S1806-37132008001200010","volume":"34","author":"DEO Vieira","year":"2008","unstructured":"Vieira DEO, Gomes M. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of S\u00e3o Paulo, Brazil. J Bras Pneumol. 2008;34:1049\u201310555.","journal-title":"J Bras Pneumol"},{"key":"1324_CR22","first-page":"531","volume":"58","author":"AK Chhetri","year":"2008","unstructured":"Chhetri AK, Saha A, Verma SC, Palaian S, Pranaya M, Shankar PR. A study of adverse drug reactions caused by first line anti-tubercular drugs used in Directly Observed Treatment, Short course (DOTS) therapy in western Nepal, Pokhara. J Pak Med Assoc. 2008;58:531\u20135.","journal-title":"J Pak Med Assoc"},{"key":"1324_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1155\/2014\/412893","volume":"25","author":"F Aliasghar","year":"2014","unstructured":"Aliasghar F, Masoomeh S, Mansoureh J, Keshavarz S. Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients. Tuberc Res Treat. 2014;25:25. https:\/\/doi.org\/10.1155\/2014\/412893.","journal-title":"Tuberc Res Treat"},{"key":"1324_CR24","first-page":"28","volume":"1","author":"LV Panova","year":"2003","unstructured":"Panova LV, Ovsiankina ES. Incidence of adverse reactions to chemotherapy and their types in adolescents with tuberculosis. Probl Tuberk. 2003;1:28\u201330.","journal-title":"Probl Tuberk"},{"key":"1324_CR25","doi-asserted-by":"publisher","first-page":"961","DOI":"10.5588\/ijtld.11.0574","volume":"167","author":"MW Carroll","year":"2012","unstructured":"Carroll MW, Lee M, Cai Y, Hallahan CW, Shaw PA, Min JH, et al. Frequency of adverse reactions to first and second line anti-tuberculosis chemotherapy in a Korean cohort. Int J Tuberc Lung Dis. 2012;167:961\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1324_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.anai.2015.04.015","volume":"115","author":"GK Buhari","year":"2015","unstructured":"Buhari GK, Keren M, Dursun AB, G\u00fcler M, Dulkar G, Kala\u00e7 N, et al. Immediate-type hypersensitivity reactions due to antituberculosis drugs: a successful readministration protocol. Ann Allergy Asthma Immunol. 2015;115:39\u201344.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1324_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0962-8479(96)90073-8","volume":"77","author":"LP Ormerod","year":"1996","unstructured":"Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis. 1996;77:37\u201342.","journal-title":"Tuber Lung Dis"},{"key":"1324_CR28","first-page":"144","volume":"21","author":"ATE Castro","year":"2015","unstructured":"Castro ATE, Mendesb M, Freitasa Roxo PC. Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years. Rev Port Pneumol. 2015;21:144\u201350.","journal-title":"Rev Port Pneumol"},{"key":"1324_CR29","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.rmed.2006.01.014","volume":"100","author":"BE G\u00fclbay","year":"2006","unstructured":"G\u00fclbay BE, G\u00fcrkan OU, Y\u0131ld\u0131z OA, Onen ZP, Erkeko FO, Ba\u00e7\u00e7io\u011flu A, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med. 2006;100:1834\u201342.","journal-title":"Respir Med"},{"key":"1324_CR30","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","volume":"167","author":"D Yee","year":"2003","unstructured":"Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1324_CR31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0041-3879(82)80018-4","volume":"63","author":"LJ Gonzalez Montaner","year":"1982","unstructured":"Gonzalez Montaner LJ, Dambrosi A, Manassero Vilar M, Dambrosi ML. Adverse effects of antituberculosis drugs causing changes in treatment. Tubercle. 1982;63:291\u20134.","journal-title":"Tubercle"},{"key":"1324_CR32","first-page":"143","volume":"62","author":"WC Tan","year":"2007","unstructured":"Tan WC, Ong CK, Kang SCL, Razak MA. Two years review of cutaneous adverse drug reaction from first line antituberculous drugs. Med J Malaysia. 2007;62:143\u20135.","journal-title":"Med J Malaysia"},{"key":"1324_CR33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1365-3156.2009.02449.x","volume":"15","author":"A Tostmann","year":"2010","unstructured":"Tostmann A, Boogaard JVD, Semvua H, Kisonga R, Kibiki GS, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients. Trop Med Int Health. 2010;15:268\u201372.","journal-title":"Trop Med Int Health"},{"key":"1324_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s12157-010-0155-4","volume":"4","author":"MJ Lohoues-Kouacou","year":"2010","unstructured":"Lohoues-Kouacou MJ, Mahassadi Kouam\u00e9 C, Houedanou E, Allah-Kouadio E, Assi C, Kamat\u00e9 M, et al. Incidence and risk factors of antituberculous drug-induced hepatitis among black Africans patients in early phase of antituberculous treatment. J Afr H\u00e9pato-Gastroent\u00e9rol. 2010;4:81\u20138.","journal-title":"J Afr H\u00e9pato-Gastroent\u00e9rol"},{"key":"1324_CR35","first-page":"13","volume":"83","author":"Y Kaneko","year":"2008","unstructured":"Kaneko Y, Nagayama N, Kawabe Y, Shimada M, Suzuki J, Kunoji M, et al. Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis. Kekkaku. 2008;83:13\u20139.","journal-title":"Kekkaku"},{"key":"1324_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1378\/chest.99.2.465","volume":"99","author":"MA Steele","year":"1991","unstructured":"Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampicin. A meta-analysis. Chest. 1991;99:465\u201371.","journal-title":"Chest"},{"key":"1324_CR37","first-page":"995","volume":"6","author":"AM Lee","year":"2002","unstructured":"Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis. 2002;6:995\u20131000.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1324_CR38","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7326\/0003-4819-137-8-200210150-00007","volume":"137","author":"RM Jasmer","year":"2002","unstructured":"Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002;137:640\u20137.","journal-title":"Ann Intern Med"},{"key":"1324_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1378\/chest.123.1.102","volume":"123","author":"L McNeill","year":"2003","unstructured":"McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest. 2003;123:102\u20136.","journal-title":"Chest"},{"key":"1324_CR40","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.rmr.2010.10.034","volume":"28","author":"J Perriot","year":"2011","unstructured":"Perriot J, Chambonnet E, Eschalier A. Les effets ind\u00e9sirables des antituberculeux; prise en charge. Revue des Mal Respir. 2011;28:542\u201355.","journal-title":"Revue des Mal Respir"},{"key":"1324_CR41","first-page":"82","volume":"66","author":"L Fekih","year":"2011","unstructured":"Fekih L, Boussoffara L, Fenniche S, Abdelghaffar H, Megdiche ML. Neuropsychiatric side effects of antituberculosis agents. Rev Med Liege. 2011;66:82\u20135.","journal-title":"Rev Med Liege"},{"key":"1324_CR42","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2165\/11534340-000000000-00000","volume":"24","author":"JS Kass","year":"2010","unstructured":"Kass JS. Shandera WX (2006) Nervous system\u00a0effects\u00a0of\u00a0antituberculosis\u00a0therapy. CNS Drugs. 2010;24:655\u20137.","journal-title":"CNS Drugs"},{"key":"1324_CR43","first-page":"56","volume":"12","author":"R Chan","year":"2006","unstructured":"Chan R, Kwok A. Ocular toxicity of ethambutol. Hong Kong Med J. 2006;12:56\u201360.","journal-title":"Hong Kong Med J"},{"key":"1324_CR44","unstructured":"World Health Organization (2008) Global tuberculosis control 2008. In: Surveillance, planning, financing Geneva."},{"key":"1324_CR45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ejcdt.2017.10.006","volume":"66","author":"RM Nafae","year":"2017","unstructured":"Nafae RM, Elshahat HM, Said AM, Ibrahim M. Reviewing treatment outcomes of tuberculosis patients at Zagazig Chest Hospital (2008\u20132012). Egypt J Chest Dis Tuberc. 2017;66:623\u201330.","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"1324_CR46","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/1471-2458-9-292","volume":"9","author":"W Jianming","year":"2009","unstructured":"Jianming W, Hongbing S. Review of cigarette smoking and tuberculosis in China intervention is needed for smoking cessation among tuberculosis patients. BMC Public Health. 2009;9:292. https:\/\/doi.org\/10.1186\/1471-2458-9-292.","journal-title":"BMC Public Health"},{"key":"1324_CR47","first-page":"258","volume":"7","author":"T Santha","year":"2002","unstructured":"Santha T, Garg R, Frieden T, et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS program in Tiruvallur District, South India. Int J Tuberc Lung Dis. 2002;7:258\u201365.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1324_CR48","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/1471-2458-9-371","volume":"9","author":"T Belay","year":"2009","unstructured":"Belay T, Abebe M, Assegdech D, et al. Treatment outcome of tuberculosis patients at Gondar University Teaching Hospital, Northwest Ethiopia. a 5-year retrospective study. BMC Public Health. 2009;9:371\u201380.","journal-title":"BMC Public Health"},{"issue":"5","key":"1324_CR49","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.bjid.2012.12.010","volume":"17","author":"B Getahun","year":"2013","unstructured":"Getahun B, Ameni G, Medhin G, Biadgilign S. Treatment outcome of tuberculosis patients under directly observed treatment in Addis Ababa, Ethiopia. Braz J Infect Dis. 2013;17(5):521\u20138.","journal-title":"Ethiopia. Braz J Infect Dis."},{"key":"1324_CR50","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ejcdt.2016.05.007","volume":"65","author":"S Khazaei","year":"2016","unstructured":"Khazaei S, Zadeh JH, Rezaeianc S, Ghaderi E, Khazaei S, Hafshejani AM, Salehiniya H, Zahirii A. Treatment outcome of new smear positive pulmonary tuberculosis patients in Hamadan, Iran: a registry-based cross-sectional study. Egypt J Chest Dis Tuberc. 2016;65:825\u201330.","journal-title":"Egypt J Chest Dis Tuberc."},{"key":"1324_CR51","first-page":"1","volume":"106","author":"L Jen-Jyh","year":"2017","unstructured":"Jen-Jyh L, Rong-Lun Wu, Yeong-Sheng L, Yi-Chun Wu, Chen-Yuan C. Treatment outcome of pulmonary tuberculosis in eastern Taiwan\u2014experience at a medical center. J Formos Med Assoc. 2017;106:1.","journal-title":"J Formos Med Assoc."},{"key":"1324_CR52","first-page":"611","volume":"12","author":"A Faustini","year":"2008","unstructured":"Faustini A, Hall AJ, Mantovani J, Sangalli M, Perucci CA. Treatment outcomes and relapses of pulmonary tuberculosis in Lazio, Italy, 1999\u20132001: a 6-year follow-up study. J Infect Dis. 2008;12:611\u201321.","journal-title":"J Infect Dis."}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-019-01324-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-019-01324-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-019-01324-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:19:33Z","timestamp":1659097173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-019-01324-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1324"],"URL":"https:\/\/doi.org\/10.1007\/s15010-019-01324-3","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]},"assertion":[{"value":"24 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the Faculty of Medicine and Pharmacy, Rabat under the reference number 706\/2014. The study was based in accordance with the Declaration of Helsinki. Regarding minor patients, informed consent to participate in the study was obtained from patients or legal guardian. All patient data were rendered anonymous before analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The raw data on which conclusions of this manuscript rely are available upon request. Please contact Mariam El hamdouni at mariam.elhamdouni@gmail.com.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}